dopamine d2 receptor การใช้

• See " Cdk5 Phosphorylates Dopamine D2 Receptor and Attenuates Downstream Signaling " ( 2013)
• Extrapyramidal symptoms are most commonly caused by typical antipsychotic drugs that antagonize dopamine D2 receptors.
• There are inconsistent findings about an additional activity as a dopamine D2 receptor partial agonist.
• This led to further research that the medication itself was a cause for the increase of dopamine D2 receptors.
• However, people with bulimia nervosa may share dopamine D2 receptor-related vulnerabilities with those with substance abuse disorders.
• Currently, only one drug, metoclopramide, dopamine D2 receptor antagonist, is FDA approved for the treatment of gastroparesis in the US.
• Furthermore, Bradaia et al . reported a functional link between TAAR1 and the dopamine D2 receptors where antagonism of TAAR1 with EPPTB resulted in an increased dopamine D2 receptor agonist potency . . ..
• Furthermore, Bradaia et al . reported a functional link between TAAR1 and the dopamine D2 receptors where antagonism of TAAR1 with EPPTB resulted in an increased dopamine D2 receptor agonist potency . . ..
• Further studies by Espinoza et al ., showed formation of heterodimers between the dopamine D2 receptor and TAAR1 in HEK cells and that haloperidol treatment ( a D2 dopamine receptor antagonist ) enhanced TAAR1 signalling in these cells.
• In addition NCS-1 is significant in intelligence in creating curiosity by its function on dopamine D2 receptors in the dentate gyrus, increasing memory for complex tasks . http : / / www . physorg . com / news172174436 . html
• Symptoms of schizophrenia may arise out of'the aberrant assignment of salience to external objects and internal representations', and antipsychotic medications reduce positive symptoms, by attenuating aberrant motivational salience, via blockade of the dopamine D2 receptors ( Kapur, 2003 ).
• In vivo TAAR1 D2 functional interaction + distinct DA effects in dorsal / ventral striatal neurons : Bradaia et al . discovered that antagonism of TAAR1 in mouse brain slices resulted in increased dopamine D2 receptor agonist potency ( Bradaia et al ., 2009 ).
• Symptoms of schizophrenia and schizotypy may arise out of  the aberrant assignment of salience to external objects and internal representations, and antipsychotic medications reduce positive symptoms, by attenuating aberrant motivational salience, via blockade of the Dopamine D2 receptors ( Kapur, 2003 ).
• Dr . Blum is known for originating the idea that alcoholism is associated with the Dopamine D2 Receptor gene as well as the concept of Reward Deficiency Syndrome with has been published in the Journal of the Royal Society of Medicine-a peer review medical journal.
• For example, the antipsychotic Aripirazole causes antagonism of Dopamine D2 receptors in areas such as the Mesolimbic area of the brain ( which show increased dopamine activity in psychosis ), but also agonism of Dopamine receptors in areas of dopamine hypoactivity, such as the mesocortical area.
• The importance of the dopamine theory has been further strengthened by the finding for common variant in the dopamine D2 receptor as candidate loci for the disease, as identified by the large genome-wide association study which included over 35.000 cases and over 110.000 controls.
• Indeed, in animal studies low dopamine D2 receptors, caused by addiction, are associated with impulsivity . ( " Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects : Possible contributing factors " ) Moreover, causation has been established in both animal and human addicts.
• While initially thought to be a heterodimer, a 2015 review indicated that the A2A-DRD2 complex is a heterotetramer composed of A2A and DRD2 homodimers ( i . e ., this heterotetramer is a complex of four GPCRs that is composed of two adenosine A2A receptors and two dopamine D2 receptors ).
• The study, which appeared in the Sept . 1, 1999, American Journal of Psychiatry, found that people who have lower levels of dopamine D2 receptors in their brains are more likely to enjoy the effects of methylphenidate, a mild stimulant, than people who have higher levels of these receptors and who were found to dislike the drug's effects.